NHG-Richtlijnen
NHG-Standaard
M73
3.1
juni 2022
februari 2024
W/X/Y. Zwangerschap / anticonceptie / geslachtsorganen man en vrouw

Begrippen

Naar Volledige tekst ›

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Differentiaaldiagnostische overwegingen

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Voorlichting

Naar Volledige tekst ›

Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Hormoontherapie algemeen

Naar Volledige tekst ›

Niet-hormonale behandeling

Naar Volledige tekst ›

Vaginale klachten

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Consultatie en verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Afstemming

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Etiologie, prognose en beloop

Naar Samenvatting ›

Follikelstimulerend hormoon

Naar Samenvatting ›

Klachten tijdens de overgang

Naar Samenvatting ›

Opvliegers

Naar Samenvatting ›

Vulvovaginale atrofie

Naar Samenvatting ›

Beloop

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Ten behoeve van de differentiaaldiagnose

Naar Samenvatting ›

Gevolgen voor de vrouw

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

Bepaling FSH, LH en oestradiol

Naar Samenvatting ›

Mammografie

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Voorlichting

Naar Samenvatting ›

Thuisarts

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

Gewichtsreductie

Naar Samenvatting ›

Lichaamsbeweging

Naar Samenvatting ›

Stressreducerende psychologische interventie

Naar Samenvatting ›

Vrij verkrijgbare preparaten

Naar Samenvatting ›
Zilverkaars
Naar Samenvatting ›
Fyto-oestrogenen
Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Hormoontherapie algemeen

Naar Samenvatting ›
Voor- en nadelen
Naar Samenvatting ›
Vrouwen met risicofactoren
Naar Samenvatting ›

Hormoontherapie, keuze van medicatie

Naar Samenvatting ›
Estradiol oraal of transdermaal
Naar Samenvatting ›
Voorkeurstoedieningsvorm transdermaal estradiol
Naar Samenvatting ›
Monotherapie estradiol of combinatietherapie estradiol met progestageen
Naar Samenvatting ›
Type progestageen
Naar Samenvatting ›
Progestageen continu of sequentieel
Naar Samenvatting ›
Perimenopauzale vrouwen met anticonceptiewens
Naar Samenvatting ›
Tibolon
Naar Samenvatting ›

Hormoontherapie, praktische uitwerking

Naar Samenvatting ›

Niet-hormonale behandeling

Naar Samenvatting ›
Clonidine
Naar Samenvatting ›
Antidepressiva
Naar Samenvatting ›
Gabapentine
Naar Samenvatting ›

Vaginale klachten

Naar Samenvatting ›

Controles

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Vaginaal bloedverlies

Naar Samenvatting ›

Referenties

  1. Heineman MJ, Evers JLH, Massuger LFAG, Steegers EAP. Obstetrie en gynaecologie. De voortplanting van de mens. 6e dr. Maarssen: Elsevier Gezondheidszorg, 2007.
  2. WHO. Research on the menopause in the 1990s. Report of WHO Scientific Group (1996). Geraadpleegd juni 2022. Ga naar bron
  3. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Pract Res Clin Obstet Gynaecol 2009;23:7-23.
  4. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-8.
  5. Nelson HD. Menopause. Lancet 2008;371:760-70.
  6. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet 2010;376:911-21.
  7. Van Disseldorp J, Faddy MJ, Themmen AP, De Jong FH, Peeters PH, Van der Schouw YT et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008;93:2129-34.
  8. Kok HS, Van Asselt KM, Van der Schouw YT, Grobbee DE, Te Velde ER, Pearson PL et al. Subfertility reflects accelerated ovarian ageing. Hum Reprod 2003;18:644-8.
  9. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. The climacteric and well-being. J Psychosom Obstet Gynaecol 1993;14:127-43.
  10. Parente RC, Faerstein E, Celeste RK, Werneck GL. The relationship between smoking and age at the menopause: A systematic review. Maturitas 2008;61:287-98.
  11. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, Skurnick J. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-74.
  12. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006;96:1226-35.
  13. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168(3 Pt 1):772-80.
  14. Groeneveld FP, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Vasomotor symptoms and well-being in the climacteric years. Maturitas 1996;23(3):293-9.
  15. El Khoudary SR, Greendale G, Crawford SL, Avis NE, Brooks MM, Thurston RC, et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause 2019;26(10):1213-27.
  16. Col NF, Guthrie JR, Politi, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009;16:453-7.
  17. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175(4):531-9.
  18. Tepper PG, Brooks MM, Randolph Jr JF, Sybil L. Crawford SL, El Khoudary SR, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause 2016;23:1067-74.
  19. Freeman EW, Sammel MD, Richard J. Sanders RJ. Risk of long term hot flashes after natural menopause: evidence from the Penn Ovarian Aging cohort. Menopause 2014;21:924-32.
  20. Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C et al. Management of menopause-related symptoms. 120, 1-916. 2005. Rockville, Agency for Healthcare Research and Quality.
  21. Nielen MM, Hek K, Schermer TR. Jaarcijfers aandoeningen: incidenties en prevalenties. Uit: NIVEL Zorgregistraties Eerste Lijn. Utrecht: NIVEL 2020. Geraadpleegd augustus 2021 Ga naar bron
  22. Burger H. The menopausal transition-endocrinology. J Sex Med 2008;5:2266-73.
  23. Rebbeck TR, Su HI, Sammel MD, Lin H, Tran TV, Gracia CR et al. Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause 2010;17:1026-34.
  24. Ayers B, Forshaw M, Hunter MS. The impact of attitudes towards the menopause on women's symptom experience: a systematic review. Maturitas 2010;65:28-36.
  25. Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging? Menopause 2009;16:1021-29.
  26. Pien GW, Sammel MD, Freeman EW, Lin H, DeBlasis TL. Predictors of sleep quality in women in the menopausal transition. Sleep 2008;31:991-9.
  27. DeLamater J, Karraker A. Sexual functioning in older adults. Curr Psychiatry Rep 2009;11:6-11.
  28. Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ 2010;340:c810.
  29. Van Lunsen RH, Laan E. Genital vascular responsiveness and sexual feelings in midlife women: psychophysiologic, brain, and genital imaging studies. Menopause 2004;11:741-8.
  30. Avis NE, Brockwell S, Randolph JF, Jr., Shen S, Cain VS, Ory M et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009;16:442-52.
  31. Laan E, Van Lunsen RH. Hormones and sexuality in postmenopausal women: a psychophysiological study. J Psychosom Obstet Gynaecol 1997;18:126-33.
  32. Laan E, Van Driel E, Van Lunsen RHW. Seksuele reacties van vrouwen met een seksuele opwindingsstoornis op visuele seksuele stimuli. Tijdschr Seksuol 2003;27:1-13.
  33. Potter JE. A 60-year-old woman with sexual difficulties. JAMA 2007;297:620-33.
  34. Vesco KK, Haney EM, Humphrey L, Fu R, Nelson HD. Influence of menopause on mood: a systematic review of cohort studies. Climacteric 2007;10:448-65.
  35. De Klerk BM, Schiphof D, Groeneveld FP, Koes BW, Van Osch GJ, Van Meurs JB et al. No clear association between female hormonal aspects and osteoarthritis of the hand, hip and knee: a systematic review. Rheumatology (Oxford) 2009;48:1160-5.
  36. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-36.
  37. Sturdee DW. The menopausal hot flush-anything new? Maturitas 2008;60:42-9.
  38. Franco OH, Muka T, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al, Vasomotor symptoms in women and cardiovascular risk markers: systematic review and meta-analysis. Maturitas 2015;81:353-61.
  39. Dam V, Dobson AJ, Onland-Moret NC, Van der Schouw YT , Mishra GD. Vasomotor menopausal symptoms and cardiovascular disease risk in midlife: a longitudinal study. Maturitas 2020;133:32-41.
  40. Zhu D, Chung HF, Dobson AJ, Pandeya N, Debra J. Anderson DJ, et al. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol 2020;223(6):898.
  41. Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM, Mattews KA, et al. Menopausal vasomotor symptoms and risk of incident cardiovascular disease events in SWAN. J Am Heart Assoc 2021;10:e017416.
  42. Mansfield PK, Carey M, Anderson A, Barsom SH, Koch PB. Staging the menopausal transition: data from the TREMIN Research Program on Women's Health. Womens Health Issues 2004;14:220-6.
  43. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
  44. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967;12:77-126.
  45. Taffe J, Dennerstein L. Time to the final menstrual period. Fertil Steril 2002;78:397-403.
  46. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997;27:203-14.
  47. Faughnan M, Lepage R, Fugere P, Bissonnette F, Brossard JH, D'Amour P. Screening for thyroid disease at the menopausal clinic. Clin Invest Med 1995;18:11-8.
  48. Van der Linden MW, Westert GP, De Bakker DH, Schellevis FG. Tweede Nationale Studie naar ziekten en verrichtingen in de huisartspraktijk: klachten en aandoeningen in de bevolking en in de huisartspraktijk. Utrecht/Bilthoven: NIVEL/RIVM, 2004.
  49. Van der Feltz-Cornelis CM. Therapieresistentie opvliegers bij vrouwen in de overgang: paniekstoornis? Ned Tijdschr Geneeskd 2001;281-4.
  50. Bastian LA, Smith CM, Nanda K. Is this woman perimenopausal? JAMA 2003;289:895-902.
  51. Kahwati LC, Haigler L, Rideout S, Markova T. What is the best way to diagnose menopause? J Fam Pract 2005;54:1000-2.
  52. Lambalk CB, Van Disseldorp J, De Koning CH, Broekmans FJ. Testing ovarian reserve to predict age at menopause. Maturitas 2009;63:280-91.
  53. NABON/NIV. Richtlijn Borstkanker. Utrecht: NABON/NIV 2020. Geraadpleegd december 2021. Ga naar bron
  54. Van Rossum MM, van der Avoort IAM, de Hoop D, Dukel L, van der Vleuten CJM, de Hullu JA. Lichen sclerosus. Ned Tijdschr Geneeskd 2007;151:1225-31.
  55. Smith YR, Haefner HK. Vulvar lichen sclerosus : pathophysiology and treatment. Am J Clin Dermatol 2004;5:105-25.
  56. Gold EB, Crawford SL, Shelton JF, Tepper PG, Crandall CJ, Greendale GA, et al. Longitudinal analysis of changes in weight and waist circumference in relation to incident vasomotor symptoms: the study of women' health across the nation (SWAN). Menopause 2017;24(1):9-26.
  57. Huang AJ, Subak LL, Wing R, West DS, Hernandez AL, Macer J, et al. An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med 2010;170:1161-7.
  58. Kroenke CH, Caan BJ, Stefanick ML, Anderson G, Brzyski R, Johnson KC, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause 2012;19(9):980-8.
  59. Thurston RC, Ewing LJ, Low CA, Christie AJ, Levine MD. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause 2015;22(1):59-65.
  60. Subak LL, Wing R, West DL, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Eng J Med 2009;360(5):481-90.
  61. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014:CD006108.
  62. Reed SD, Guthrie KA, Newton KM, Anderson GL, Booth-LaForce C, Caan B, et al. Menopausal quality of life: RCT of yoga, exercise and omega-3 supplements. Am J Obstet Gynecol 2014a;210:244.
  63. Daley A, Thomas A, Roalfe AK, Stokes-Lampard H, Coleman S, Rees M, et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial. BJOG 2015;122:565-75.
  64. Asghari M, Mirghafourvand M, Charandabi SMA, Nedjat S. Effect of aerobic exercise and nutrition education on quality of life and early menopause symptoms: a randomized controlled trial. Women Health 2017;57(2):173-88.
  65. Duijts SFA, Van Beurden M, Oldenburg HSA, Hunter MS, Kieffer JM, Stuiver MM, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30(33):4124-33.
  66. Tran S, Hickey M, Saunders C, Ramage L, Cohen PA. Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors. Support Care Cancer 2021;29(3):1183-93.
  67. Carcelén-Fraile MD, Aibar-Almazán A, Martínez-Amat A, Cruz-Díaz D, Díaz-Mohedo E, Redecillas-Peiró MT, et al. Effects of physical exercise on sexual function and quality of sexual life related to menopausal symptoms in peri- and postmenopausal women: a systematic review. Int J Environ Res Public Health 2020;17(8):2680.
  68. Nguyen TM, Do TTT, Tran TN, Kim JH. Exercise and quality of life in women with menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health 2020;17:7049.
  69. Javadivala Z, Allahverdipour H, Jafarabadi MA, Emami A. An interventional strategy of physical activity promotion for reduction of menopause symptoms. Health Promot Perspect 2020;10(4):383-92.
  70. Berin E, Hammar M, Lindblom H, Lindh-Åstrand L, Spetz Holm AC. Effects of resistance training on quality of life in postmenopausal women with vasomotor symptoms. Climacteric 2022;25(3):264-70.
  71. Van Driel CM, Stuursma A, Schroevers MJ, Mourits MJ, de Bock GH. Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. BJOG 2019;126(3):330-9.
  72. Hardy C, Griffiths A, Norton S, Hunter MS. Self-help cognitive behavior therapy for working women with problematic hot flushes and night sweats (MENOS@Work): a multicenter randomized controlled trial. Menopause 2018;25(5):508-19.
  73. Wong C, Yip BH, Gao T, Lam KYY, Woo DMS, Yip ALK, et al. Mindfulness-based stress reduction (MBSR) or psychoeducation for the reduction of menopausal symptoms: a randomized, controlled clinical trial. Sci Rep 2018;8(1):6609.
  74. Atema V, Van Leeuwen M, Kieffer JM, Oldenburg HSA, Van Beurden M, Gerritsma MA, et al. Efficacy of internet-based cognitive behavioral therapy for treatment-Induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2019;37(10):809-22.
  75. Fenlon D, Maishman T, Day L, Nuttall J, May C, Ellis M, et al. Effectiveness of nurse-led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial. Psychooncology 2020;29(10):1514-23.
  76. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012:CD007244.
  77. Shahnazi M, Nahaee J, Charandabi SMA, Bayatipayan S. Effect of black cohosh (cimicifuga racemosa) on vasomotor symptoms in postmenopausal women: a randomized clinical trial. J Caring Sci 2013;2(2):105-13.
  78. Tanmahasamut P, Vichinsartvichai P, Rattanachaiyanont M, Techatraisak K, Dangrat C, Sardod P. Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. Climacteric 2015;18(1):79-85.
  79. Lareb. Herbal preparations with phytoestrogens- overview of the adverse drug reactions (2019). (10 december 2019; geraadpleegd september 2020) Ga naar bron
  80. NVWA. Advies over de gezondheidsrisico's van voedingssupplementen die zilverkaars bevatten (2020). Geraadpleegd september 2020. Ga naar bron
  81. Najaf Najafi M, Ghazanfarpour M. Effect of phytoestrogens on sexual function in menopausal women: a systematic review and meta-analysis. Climacteric 2018;21(5):427-45.
  82. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016;315(23):2554-63.
  83. Perna S, Peroni G, Miccono A, Riva A, Morazzoni P. Allegrini P, et al. Multidimensional effects of soy isoflavone by food or supplements in menopause women: a systematic review and bibliometric analysis. Nat Prod Commun 2016;11(11):1733-40.
  84. Jenabi E, Shobeiri F, Hazavehei SMM, Roshanaei G. The effect of valerian on the severity and frequency of hot flashes: a triple-blind randomized clinical trial. Women Health 2018;58(3):297-304.
  85. Li J, Li H, Yan P, Gio L, Li J, Han J, et al. Efficacy and safety of phytoestrogens in the treatment of perimenopausal and postmenopausal depressive disorders: a systematic review and meta-analysis. Int J Clin Pract 2021;75(10):e14360.
  86. Wang Y, Hernandez G, Mack WJ, Schneider LS, Yin F, Brinton RD. Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy. Menopause 2020;27(1):57-65.
  87. Frigo M, De Barros E, Dos Santos PC, Peres GL, Weber J, Zanelatto C, et al. Effects of a cereal bar with a combination of phytoestrogens on the climacteric symptoms: a placebo-controlled, randomized trial. J Am Nutr Assoc 2022;41(3)325-332.
  88. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012:CD000402.
  89. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-92.
  90. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;CD000402.
  91. Grant MD, Marbella A, Wang AT, Pines E, Hoag J, Bonnell C, et al. Menopausal symptoms: comparative effectiveness of therapies [Internet]. Rockville (MD): agency for healthcare research and quality (US); 2015 Mar. Report No.: 15-EHC005-EF.
  92. Sarri G, Pedder H, Dias S, Guo Y, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG 2017;124(10):1514-23.
  93. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev.2017:CD004143.
  94. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394(10204):1159-68.
  95. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014;142:83-9.
  96. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res 2018;168:83-95.
  97. Bhupathiraju SN, Grodstein F, Rosner BA, Stampfer MJ, Hu FB, Willett WC, et al. Hormone therapy use and risk of chronic disease in the nurses' health study: a comparative analysis with the women's health initiative. Am J Epidemiol 2017;186(6):696-708.
  98. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114(3):448-54.
  99. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103-11.
  100. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29(21):2660-8.
  101. Mørch LS, Kjaer SK, Keiding N, Løkkegaard E, Lidegaard Ø. The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. Int J Cancer 2016;138(6):1506-15.
  102. Løkkegaard E, Nielsen LH, Keiding N. Risk of stroke with various types of menopausal hormone therapies: a national cohort study. Stroke 2017;48(8):2266-9.
  103. Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009a;12(5):445-53.
  104. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019 9;364:k4810.
  105. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873.
  106. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483-9.
  107. Moermond CTA et al. Rijksinstituut voor Volksgezondheid en Milieu. Medicijnresten en waterkwaliteit: een update. 2020.
  108. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al ; PROSE Study Group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23(31):7804-10.
  109. NVOG. Richtlijn Management rondom de menopauze (2018). Module Overgangsklachten bij hoog risicoprofiel. Geraadpleegd december 2021. Ga naar bron
  110. Maas AHEM, Rosano G, Cifkova R, Chieffo A, Van Dijken D, Hamoda H, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967-84.
  111. NIV. Richtlijn Antitrombotisch beleid 2016. Module Hormonale suppletie therapie en veneuze trombose. Geraadpleegd december 2021. Ga naar bron
  112. Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev 2016:CD010407.
  113. Bezwada P, Shaikh A, Misra D. The effect of transdermal estrogen patch use on cardiovascular outcomes: a systematic review. J Womens Health (Larchmt) 2017;26(12):1319-25.
  114. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, et al. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke 2016;47(7):1734-41.
  115. Shufelt CL, Merz CN, Prentice RL, Pettinger MB, Rossouw JE, Aroda VR, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the women's health initiative observational study. Menopause 2014;21(3):260-6.
  116. ESHRE Guideline endometriosis 2022. Geraadpleegd april 2022. Ga naar bron
  117. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
  118. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al; million women study collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10(11):2277-86.
  119. Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30(2):340-5.
  120. Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault MC, Clavel-Chapelon F, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol 2014a;180(5):508-17.
  121. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010 15;172(12):1394-403.
  122. Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009b;12(6):514-24
  123. Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol 2007;23(7):391-7.
  124. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011;128(7):1644-51.
  125. FSRH. Clinical guideline: Contraception for women aged over 40 years. 2019. Faculty of Sexual and Reproductive Healthcare (FSRH, UK). Geraadpleegd december 2021. Ga naar bron
  126. NVOG. Richtlijn Postmenopauzaal bloedverlies (PMB) 2015. Geraadpleegd augustus 2021. Ga naar bron
  127. NICE. Menopause: diagnosis and management – NICE guideline [NG23] (2015). Geraadpleegd augustus 2021. Ga naar bron
  128. Løkkegaard ECL, Mørch LS. Tibolone and risk of gynecological hormone sensitive cancer. Int J Cancer 2018;142:2435-40.
  129. Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016:CD008536.
  130. Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014b;145(2):535-43.
  131. L'Espérance S, Frenette S, Dionne A, Dionne JY; Comité de l'évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 2013;21(5):1461-74.
  132. Mareti E, Ampatzi C, Paschou SA, Voziki E, Goulis DG. Non-hormonal replacement therapy regimens: do they have an effect on cardiovascular risk? Curr Vasc Pharmacol 2019;17(6):573-8.
  133. Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA. Hot flushes, vascular reactivity and the role of the α-adrenergic system. Climacteri. 2012;15(4):332-8.
  134. Boekhout AH, Vincent AD, Dalesio OB, Van den Bosch J, Foekema-Töns JH, Adriaansz S, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29(29):3862-8.
  135. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132(10):788-93.
  136. Del Rio G, Menozzi R, Della Casa L, Venneri MG, Zizzo G, Marrama P, et al. Alpha-2 adrenergic activity in perimenopausal women. J Endocrinol Invest 1997;20(10):603-10.
  137. Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, et al. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014b;124(2 Pt 1):233-41.
  138. Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014;174(7):1058-66.
  139. Capriglione S, Plotti F, Montera R, Luvero D, Lopez S, Scaletta G, et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial. Gynecol Oncol 2016;143(3):584-8.
  140. Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Am J Obstet Gynecol 2020;222(6):564-79.
  141. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016:CD001500.
  142. Najjarzadeh M, Charandabi SMA, Mohammadi M, Mirghafourvand M. Comparison of the effect of hyaluronic acid and estrogen on atrophic vaginitis in menopausal women: a systematic review. Post Reprod Health 2019;25(2):100-8.
  143. Constantine GD, Graham S, Lapane K, Ohleth K, Bernick B, Liu J, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800-7.
  144. Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018;178(5):681-90.
  145. Bumphenkiatikul T, Panyakhamlerd K, Chatsuwan T, Ariyasriwatana C, Suwan A, Taweepolcharoen C, et al. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial. BMC Womens Health 2020;20(1):173.
  146. Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery 2016;4(1):69-78.
  147. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med 2013;10(6):1575-84.
  148. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 2011;283(3):539-43.
  149. Mikkola, J Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. Clin Endocrinol Metab 2015;100(12):4588-94.
  150. NVOG. Richtlijn Prematuur ovarieel falen, diagnostiek en behandeling 1.0 (2001), Geraadpleegd augustus 2021. Ga naar bron
Keuzekaart - Warmte-aanvallen (opvliegers) in de overgang (voorbehoedmiddel)
Keuzekaart - Warmte-aanvallen (opvliegers) in de overgang (geen voorbehoedmiddel)
Keuzekaart - Warmte-aanvallen (opvliegers) in de overgang (niet meer ongesteld)
NHG-werkgroep:
Blom JW, De Vries CJ, Eekhof H, Engel HF, Hoenjet E, Janssen CA, Schep A, Stevens NT, Van den Donk M, Wiersma Tj, Woudstra SJ
5 gerelateerde lacunes
E-mail